Using the iADL Scale to Predict Treatment Outcomes in Elderly Lymphoma Patients
Author Information
Author(s): Paula Jabłonowska-Babij, Magdalena Olszewska-Szopa, Stanisław Potoczek, Maciej Majcherek, Agnieszka Szeremet, Krzysztof Kujawa, Tomasz Wróbel, Anna Czyż, Vera Ulrike Bacher
Primary Institution: Wroclaw Medical University
Hypothesis
The study aims to analyze the prognostic value of selected CGA tools in predicting adverse events and outcomes of R-CHOP treatment in elderly patients with DLBCLs or MCLs.
Conclusion
The iADL scale is a significant predictor of adverse events and treatment outcomes in elderly patients with DLBCLs or MCLs treated with R-CHOP.
Supporting Evidence
- The iADL scale was significantly associated with response to treatment.
- Better performance on the iADL scale was linked to lower mortality risk.
- Patients with higher iADL scores had longer overall survival and progression-free survival.
- The study included a diverse group of elderly patients with newly diagnosed DLBCLs or MCLs.
- Statistical analyses confirmed the significance of the iADL scale in predicting treatment outcomes.
Takeaway
This study shows that a simple questionnaire about daily activities can help doctors understand how well older patients with lymphoma might respond to treatment.
Methodology
Patients underwent several assessments including the iADL scale before starting R-CHOP treatment.
Potential Biases
Participants may have inaccurately reported their functional status due to social desirability or cognitive impairment.
Limitations
The study had a limited sample size and was conducted at a single center, which may affect the generalizability of the results.
Participant Demographics
The study included 62 patients, with a mean age of 72 years, consisting of 41 men and 21 women.
Statistical Information
P-Value
p = 0.03 for treatment response, p < 0.001 for overall survival, p = 0.03 for progression-free survival.
Confidence Interval
95% CI: 1.02–1.44 for treatment response, 95% CI: 0.79–0.89 for overall survival, 95% CI: 0.83–0.99 for progression-free survival.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website